Association of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic Syndrome in Adult Population: A Narrative Review
Authors
-
Experimental and Public Health Laboratory, Department of Zoology, University of Lucknow, Lucknow - 226007, Uttar Pradesh ,IN
Isha Patel -
Experimental and Public Health Laboratory, Department of Zoology, University of Lucknow, Lucknow - 226007, Uttar Pradesh ,INArti Yadav
-
Experimental and Public Health Laboratory, Department of Zoology, University of Lucknow, Lucknow - 226007, Uttar Pradesh ,INSuchit Swaroop
DOI:
https://doi.org/10.18311/jeoh/2024/36032Keywords:
Chronic Vascular Disease (CVD), NAFLD, ObesityAbstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is swiftly evolving into a prevailing liver condition on a global scale and within the United States, it stands as the primary contributor to chronic liver disease. Previously viewed as a Western disorder, obesity and NAFLD are gaining increased recognition within the Asian community. Notably, NAFLD has been observed to have strong associations with Type 2 Diabetes Mellitus (T2DM), Chronic Vascular Disease (CVD), and Chronic Kidney Disease (CKD).
Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Isha Patel, Arti Yadav, Suchit Swaroop
This work is licensed under a Creative Commons Attribution 4.0 International License.
Accepted 2024-02-26
Published 2024-04-05
References
Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018; 18(3):245-50. https:// doi.org/10.7861/clinmedicine.18-3-245 PMid:29858436 PMCid: PMC6334080. DOI: https://doi.org/10.7861/clinmedicine.18-3-245
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non- Alcoholic Fatty Liver Disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22(1):63. https://doi. org/10.1186/s12902-022-00980-1 PMid:35287643 PMCid: PMC8919523. DOI: https://doi.org/10.1186/s12902-022-00980-1
Yan H, Wu W, Chang X, Xia M, Ma S, Wang L, Gao J. Gender differences in the efficacy of pioglitazone treatment in non-alcoholic fatty liver disease patients with abnormal glucose metabolism. Biology of Sex Differences. 2021; 12(1):1-8. https://doi.org/10.1186/s13293-020-00344-1 PMid:33397443 PMCid: PMC7784274. DOI: https://doi.org/10.1186/s13293-020-00344-1
Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020; 12:60. https://doi. org/10.1186/s13098-020-00570-y PMid:32684985 PMCid: PMC7359287. DOI: https://doi.org/10.1186/s13098-020-00570-y
Sarwar R, Pierce N, Koppe S. Obesity and non-alcoholic fatty liver disease: Current perspectives. Diabetes Metab Syndr Obes. 2018; 11:533-42. https://doi.org/10.2147/ DMSO.S146339 PMid:30288073 PMCid: PMC6163009. DOI: https://doi.org/10.2147/DMSO.S146339
Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-Alcoholic Fatty Liver Disease (NAFLD) in obesity. Journal of clinical and diagnostic research. 2014; 8(1):62– 66. https://doi.org/10.7860/JCDR/2014/6691.3953 DOI: https://doi.org/10.7860/JCDR/2014/6691.3953
Fabbrini E, Sullivan S, Klein S. Obesity and non-alcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology. 2010; 51(2):679-89. https:// doi.org/10.1002/hep.23280 PMid:20041406 PMCid: PMC3575093. DOI: https://doi.org/10.1002/hep.23280
Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - The link between adipocytes and hepatocytes. Digestion. 2011; 83(1-2):124-33. https://doi. org/10.1159/000318741 PMid:21042023.
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2017; 23(47):8263. https://doi. org/10.3748/wjg.v23.i47.8263 PMid:29307986 PMCid: PMC5743497. DOI: https://doi.org/10.3748/wjg.v23.i47.8263
Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013; 28(4):64-70. https://doi.org/10.1111/jgh.12271 PMid:24251707. DOI: https://doi.org/10.1111/jgh.12271
Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther. 2021; 38(5):2130-58. https://doi. org/10.1007/s12325- 021-01690-1 PMid:33829368 PMCid: PMC8107169. DOI: https://doi.org/10.1007/s12325-021-01690-1
J. Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022; 20(3):e573- 82. Epub 2021 Feb 20. PMID: 33618024. https://doi. org/10.1016/j.cgh.2021.02.030. PMid:33618024
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016; 64(1):73-84. https://doi. org/10.1002/hep.28431 PMid:26707365. DOI: https://doi.org/10.1002/hep.28431
Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int. 2022; 42(9):1955- 68. https://doi.org/10.1111/liv.15046 PMid:34459096. DOI: https://doi.org/10.1111/liv.15046
Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019; 4(5):389-98. https:// doi.org/10.1016/S2468-1253(19)30039-1 PMid:30902670. DOI: https://doi.org/10.1016/S2468-1253(19)30039-1
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-73. https://doi. org/10.1016/j.jhep.2017.06.003 PMid:28642059.
Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, Chan HL, Chim AM, Woo J, Chu WC, Wong VW. Prevalence and severity of non-alcoholic fatty liver disease in non-obese patients: A population study using protonmagnetic resonance Spectroscopy. Am J Gastroenterol. 2015; 110(9):1306-14; quiz 1315. https://doi.org/10.1038/ ajg.2015.235 PMid:26215532. DOI: https://doi.org/10.1038/ajg.2015.235
Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K, Itoh Y. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol. 2015; 50(1):95-108. https://doi.org/10.1007/ s00535-014-0948-9 PMid:24619537. DOI: https://doi.org/10.1007/s00535-014-0948-9
Im HJ, Ahn YC, Wang JH, Lee MM, Son CG. A systematic review on the prevalence of non-alcoholic fatty liver disease in South Korea. Clin Res Hepatol Gastroenterol. 2021; 45(4):101526. https://doi.org/10.1016/j.clinre.2020.06.022 PMid:32919911. DOI: https://doi.org/10.1016/j.clinre.2020.06.022
Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, Maeda M, Thin KN, Tanaka K, Takahashi Y, Itoh Y, Oniki K, Seko Y, Saruwatari J, Kawanaka M, Atsukawa M, Hyogo H, Ono M, Ogawa E, Barnett SD, Stave CD, Cheung RC, Fujishiro M, Eguchi Y, Toyoda H, Nguyen MH. The epidemiology of NAFLD and lean NAFLD in Japan: A meta- analysis with individual and forecasting analysis, 1995-2040. Hepatol Int. 2021; 15(2):366- 79. https://doi. org/10.1007/s12072-021-10143-4 PMid:33580453. DOI: https://doi.org/10.1007/s12072-021-10143-4
Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B, Dhali GK, Santra A, Chowdhury A. Non-obese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010; 51(5):1593-602. https://doi.org/10.1002/hep.23567 PMid:20222092. DOI: https://doi.org/10.1002/hep.23567
Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: Population- based study. Ann Hepatol. 2007; 6(3):161-3. https://doi.org/10.1016/ S1665-2681(19)31922- 2 PMid:17786142. DOI: https://doi.org/10.1016/S1665-2681(19)31922-2
Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non- alcoholic fatty liver disease in India: A systematic review and meta-analysis. J Clin Exp Hepatol. 2022; 12(3):818-29. https://doi.org/10.1016/j. jceh.2021.11.010 PMid:35677499 PMCid: PMC9168741. DOI: https://doi.org/10.1016/j.jceh.2021.11.010
Atri A, Jiwanmall SA, Nandyal MB, Kattula D, Paravathareddy S, Paul TV, Thomas N, Kapoor N. The prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese women - A cross-sectional study from southern India. Eur Endocrinol. 2020; 16(2):152- 55. https://doi.org/10.17925/EE.2020.16.2.152 PMid:33117448 PMCid: PMC7572172. DOI: https://doi.org/10.17925/EE.2020.16.2.152
Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome- A new worldwide definition. Lancet. 2005; 366(9491):1059- 62. https://doi.org/10.1016/S0140-6736(05)67402-8 PMid:16182882. DOI: https://doi.org/10.1016/S0140-6736(05)67402-8
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - Mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9):599-612. https://doi.org/10.1038/ s41575-021-00448-y PMid:33972770. DOI: https://doi.org/10.1038/s41575-021-00448-y
de Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of non-alcoholic Fatty Liver Disease (NAFLD) in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2020; 105(12):3842-53. https://doi.org/10.1210/clinem/dgaa575 PMid:32827432 PMCid: PMC7526735. DOI: https://doi.org/10.1210/clinem/dgaa575
Kim JS, Lê KA, Mahurkar S, Davis JN, Goran MI. Influence of elevated liver fat on circulating adipocytokines and insulin resistance in obese Hispanic adolescents. Pediatr Obes. 2012; 7(2):158-64. Epub 2012 Feb 9. https://doi. org/10.1111/j.2047-6310.2011.00014.x PMid:22434756 PMCid: PMC3767148. DOI: https://doi.org/10.1111/j.2047-6310.2011.00014.x
Budd J, Cusi K. Role of agents for the treatment of diabetes in the management of non- alcoholic fatty liver disease. Curr Diab Rep. 2020; 20(11):59. https://doi.org/10.1007/ s11892-020-01349-1 PMid:33015726. DOI: https://doi.org/10.1007/s11892-020-01349-1
Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, Zheng MH. Non- alcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018; 2(4):376-92. https://doi.org/10.1002/hep4.1155 PMid:29619417 PMCid: PMC5880194. DOI: https://doi.org/10.1002/hep4.1155
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and metaanalysis. Sci Rep. 2016; 6:33386. https://doi.org/10.1038/ srep33386 PMid:27633274 PMCid: PMC5026028. DOI: https://doi.org/10.1038/srep33386
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66(6):1138-53. https://doi.org/10.1136/gutjnl-2017-313884 PMid:28314735. DOI: https://doi.org/10.1136/gutjnl-2017-313884
Zeb I, Li D, Budoff MJ, Katz R, Lloyd-Jones D, Agatston A, Blumenthal RS, Blaha MJ, Blankstein R, Carr J, Nasir K. Non-alcoholic fatty liver disease and incident cardiac events: The multi-ethnic study of Atherosclerosis. J Am Coll Cardiol. 2016; 67(16):1965-6. https://doi.org/10.1016/j. jacc.2016.01.070 PMid:27102512. DOI: https://doi.org/10.1016/j.jacc.2016.01.070
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016 ; 65(3):589-600. https://doi.org/10.1016/j.jhep.2016.05.013 PMid:27212244. DOI: https://doi.org/10.1016/j.jhep.2016.05.013
Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: Burden and severity of subclinical cardiovascular disease among those with non-alcoholic fatty liver; should we care? Atherosclerosis. 2013; 230(2):258-67. https://doi. org/10.1016/j.atherosclerosis.2013.07.052 PMid:24075754. DOI: https://doi.org/10.1016/j.atherosclerosis.2013.07.052
Mantovani A, Mingolla L, Rigolon R, Pichiri I, Cavalieri V, Zoppini G, Lippi G, Bonora E, Targher G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol. 2016; 225:387-91. https://doi.org/10.1016/j.ijcard.2016.10.040 PMid:27768965. DOI: https://doi.org/10.1016/j.ijcard.2016.10.040
Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between heart disease and metabolic steatosis: A contemporary perspective. J Clin Med. 2021; 10(8):1569. https://doi.org/10.3390/jcm10081569 PMid:33917867 PMCid: PMC8068259. DOI: https://doi.org/10.3390/jcm10081569
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Nonalcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis. Gut. 2022; 71(1):156-62. https://doi.org/10.1136/gutjnl-2020-323082 PMid:33303564. DOI: https://doi.org/10.1136/gutjnl-2020-323082
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; 67(4):862-73. https://doi. org/10.1016/j.jhep.2017.06.003 PMid:28642059. DOI: https://doi.org/10.1016/j.jhep.2017.06.003
Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - T he link between adipocytes and hepatocytes. Digestion. 2011; 83(1-2):124-33. https://doi. org/10.1159/000318741 PMid:21042023. DOI: https://doi.org/10.1159/000318741
Osorio-Conles Ó, Vega-Beyhart A, Ibarzabal A, Balibrea JM, Graupera I, Rimola J, idal J, de Hollanda A. A distinctive NAFLD signature in adipose tissue from women with severe obesity. Int J Mol Sci. 2021; 22(19):10541. https:// doi.org/10.3390/ijms221910541 PMid:34638880 PMCid: PMC8509058. DOI: https://doi.org/10.3390/ijms221910541
Zhang HJ, He J, Pan LL, Ma ZM, Han CK, Chen CS, Chen Z, Han HW, Chen S, Sun Q, Zhang JF, Li ZB, Yang SY, Li XJ, Li XY. Effects of moderate and vigorous exercise on non- alcoholic fatty liver disease: A randomized clinical trial. JAMA Intern Med. 2016; 176(8):1074-82. https://doi. org/10.1001/jamainternmed.2016.3202 PMid:27379904. DOI: https://doi.org/10.1001/jamainternmed.2016.3202
Mascaró CM, Bouzas C, Montemayor S, Casares M, Llompart I, Ugarriza L, Borràs PA, Martínez JA, Tur JA. Effect of a six-month lifestyle intervention on the physical activity and fitness status of adults with NAFLD and metabolic syndrome. Nutrients. 2022; 14(9):1813. https:// doi.org/10.3390/nu14091813 PMid:35565780 PMCid: PMC9105030. DOI: https://doi.org/10.3390/nu14091813
Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of non-alcoholic fatty liver disease: A review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016; 9(3):392-407. https://doi. org/10.1177/1756283X16638830 PMid:27134667 PMCid: PMC4830109. DOI: https://doi.org/10.1177/1756283X16638830
Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N, Rein M, Serfaty D, Kenigsbuch S, Zelicha H, Yaskolka Meir A, Tene L, Bilitzky A, Tsaban G, Chassidim Y, Sarusy B, Ceglarek U, Thiery J, Stumvoll M, Blüher M, Stampfer MJ, Rudich A, Shai I. The beneficial effects of the Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content. J Hepatol. 2019; 71(2):379-88. https:// doi.org/10.1016/j.jhep.2019.04.013 PMid:31075323. DOI: https://doi.org/10.1016/j.jhep.2019.04.013
Chen J, Huang Y, Xie H, Bai H, Lin G, Dong Y, Shi D, Wang J, Zhang Q, Zhang Y, Sun J. Impact of a low-carbohydrate and high-fiber diet on non-alcoholic fatty liver disease. Asia Pac J Clin Nutr. 2020; 29(3):483-90.
